A detailed history of Vanguard Group Inc transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,613,063 shares of ATHA stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,613,063
Previous 1,634,433 1.31%
Holding current value
$1.03 Million
Previous $4.33 Million 83.26%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$0.42 - $3.43 $8,975 - $73,299
-21,370 Reduced 1.31%
1,613,063 $725,000
Q1 2024

May 10, 2024

SELL
$2.24 - $4.15 $143,404 - $265,683
-64,020 Reduced 3.77%
1,634,433 $4.48 Million
Q2 2023

Aug 14, 2023

SELL
$2.36 - $3.59 $340,293 - $517,649
-144,192 Reduced 7.83%
1,698,453 $5.01 Million
Q1 2023

May 15, 2023

BUY
$2.26 - $4.22 $10,649 - $19,884
4,712 Added 0.26%
1,842,645 $4.61 Million
Q4 2022

Feb 10, 2023

BUY
$2.76 - $3.71 $16,292 - $21,900
5,903 Added 0.32%
1,837,933 $5.83 Million
Q3 2022

Nov 14, 2022

BUY
$2.93 - $3.96 $648,848 - $876,942
221,450 Added 13.75%
1,832,030 $5.44 Million
Q2 2022

Aug 12, 2022

BUY
$2.74 - $13.43 $272,635 - $1.34 Million
99,502 Added 6.58%
1,610,580 $4.91 Million
Q1 2022

May 13, 2022

SELL
$8.96 - $13.51 $216,500 - $326,442
-24,163 Reduced 1.57%
1,511,078 $20.4 Million
Q4 2021

Feb 14, 2022

SELL
$9.17 - $16.39 $974,239 - $1.74 Million
-106,242 Reduced 6.47%
1,535,241 $20 Million
Q3 2021

Nov 12, 2021

BUY
$9.15 - $11.09 $2.51 Million - $3.04 Million
273,884 Added 20.03%
1,641,483 $15.4 Million
Q2 2021

Aug 13, 2021

BUY
$10.24 - $20.87 $14 Million - $28.5 Million
1,367,599 New
1,367,599 $14 Million

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $24.2M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.